Document is current
Any future updates will be listed below
-
Authors
von Bahr, Joar
Suutala, Antti
Kucukel, Hakan
Kaingu, Harrison
Kinyua, Felix
Muinde, Martin
Osundwa, Kevan
Ronald, Wigina
Muinde, Jackson
Ngasala, Billy
Lundin, Mikael
Mårtensson, Andreas
Linder, Nina
Lundin, Johan
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 13 June 2025
First Online: 27 June 2025
Declarations
:
: JL and ML are founders and co-owners of Aiforia technologies Plc. JL and AS reported having a patent for Mobile Microscope pending (no.WO2017037334A1; the invention is related to the use of fluorescence imaging filters combined with inexpensive plastic lenses; all rights are with the University of Helsinki) and JL having a patent for a slide holder for an optical microscope pending (no.WO2015185805A1; related to motorization of regular microscopes).
: Ethical approval for the study was obtained from the Technical University of Mombasa Scientific and Ethics Review Committee (TUM ERC EXT/001/2020(RA), 19.4.2021) accredited by the National Commission for Science, Technology and Innovation (NACOSTI) Kenya. To be included in the study, assent from the study participant and informed written consent (in Swahili and English) from their legal guardian were required. It was emphasized that participation in the study was voluntary, and it was possible to withdraw consent at any stage. In addition, written consent was obtained from the primary school headmasters. All children participating in the study were offered a single oral dose of albendazole 400 mg by a designated clinician, according to national guidelines. Infected participants were also examined and monitored by a clinician in collaboration with the National NTD Program management. Furthermore, families of children with positive Kato-Katz smears were contacted and offered deworming treatment by the designated clinician.
